Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Zai Lab and Entasis Complete Enrollment in Global Test of New Antibacterial

publication date: Jul 28, 2021

Shanghai Zai Lab and Boston's Entasis Therapeutics have completed enrollment in a global Phase III trial of novel combination antibacterial. Entasis' SUL-DUR combines two IV antibacterial aimed at treating infections caused by Acinetobacter baumannii, including carbapenem-resistant strains. Zai enrolled one-quarter of the patients in Part A of the trial, which will evaluate the primary efficacy of the candidate. In 2018, Zai acquired China rights to SUL-DUR in a $100 million agreement. More details....

Stock Symbols: (NSDQ: ZLAB; HKEX: 9688) (NSDQ: ETTX)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.